BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 30334460)

  • 61. The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation.
    Patriarca F; Carobolante F; Zamagni E; Montefusco V; Bruno B; Englaro E; Nanni C; Geatti O; Isola M; Sperotto A; Buttignol S; Stocchi R; Corradini P; Cavo M; Fanin R
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1068-73. PubMed ID: 25754658
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Diagnosis and risk stratification in multiple myeloma.
    van de Donk NW; Sonneveld P
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):791-813. PubMed ID: 25212883
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Validation of the Freiburg Comorbidity Index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome.
    Kleber M; Ihorst G; Gross B; Koch B; Reinhardt H; Wäsch R; Engelhardt M
    Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):541-51. PubMed ID: 23810244
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Smoldering multiple myeloma: pathophysiologic insights, novel diagnostics, clinical risk models, and treatment strategies.
    Kazandjian D; Mailankody S; Korde N; Landgren O
    Clin Adv Hematol Oncol; 2014 Sep; 12(9):578-87. PubMed ID: 25654479
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The impact of genomics on the management of myeloma.
    Corre J; Avet-Loiseau H
    J Natl Compr Canc Netw; 2011 Oct; 9(10):1200-6. PubMed ID: 21975916
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Overview of recent trends in diagnosis and management of leptomeningeal multiple myeloma.
    Yellu MR; Engel JM; Ghose A; Onitilo AA
    Hematol Oncol; 2016 Mar; 34(1):2-8. PubMed ID: 25524637
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
    Hillengass J; Moehler T; Hundemer M
    Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.
    Munshi NC; Anderson KC; Bergsagel PL; Shaughnessy J; Palumbo A; Durie B; Fonseca R; Stewart AK; Harousseau JL; Dimopoulos M; Jagannath S; Hajek R; Sezer O; Kyle R; Sonneveld P; Cavo M; Rajkumar SV; San Miguel J; Crowley J; Avet-Loiseau H;
    Blood; 2011 May; 117(18):4696-700. PubMed ID: 21292777
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Presentation and risk stratification--improving prognosis for patients with multiple myeloma.
    Lonial S
    Cancer Treat Rev; 2010 May; 36 Suppl 2():S12-7. PubMed ID: 20472183
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial.
    Nemec P; Zemanova Z; Kuglik P; Michalova K; Tajtlova J; Kaisarova P; Oltova A; Filkova H; Holzerova M; Balcarkova J; Jarosova M; Rabasova J; Hruba M; Spicka I; Gregora E; Adam Z; Scudla V; Maisnar V; Schutzova M; Hajek R;
    Leuk Lymphoma; 2012 May; 53(5):920-7. PubMed ID: 22023516
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Risk stratification in the era of novel therapies.
    San-Miguel J; Mateos MV; Gutierrez NC
    Cancer J; 2009; 15(6):457-64. PubMed ID: 20010164
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Molecular profiling of multiple myeloma: from gene expression analysis to next-generation sequencing.
    Agnelli L; Tassone P; Neri A
    Expert Opin Biol Ther; 2013 Jun; 13 Suppl 1():S55-68. PubMed ID: 23614397
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Evolving diagnostic criteria for multiple myeloma.
    Rajkumar SV
    Hematology Am Soc Hematol Educ Program; 2015; 2015():272-8. PubMed ID: 26637733
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Current and future biomarkers for risk-stratification and treatment personalisation in multiple myeloma.
    Lê GN; Bones J; Coyne M; Bazou D; Dowling P; O'Gorman P; Larkin AM
    Mol Omics; 2019 Feb; 15(1):7-20. PubMed ID: 30652172
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis.
    Bødker JS; Brøndum RF; Schmitz A; Schönherz AA; Jespersen DS; Sønderkær M; Vesteghem C; Due H; Nørgaard CH; Perez-Andres M; Samur MK; Davies F; Walker B; Pawlyn C; Kaiser M; Johnson D; Bertsch U; Broyl A; van Duin M; Shah R; Johansen P; Nørgaard MA; Samworth RJ; Sonneveld P; Goldschmidt H; Morgan GJ; Orfao A; Munshi N; Johnson HE; El-Galaly T; Dybkær K; Bøgsted M
    Blood Adv; 2018 Sep; 2(18):2400-2411. PubMed ID: 30254104
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma.
    Paiva B; Chandia M; Puig N; Vidriales MB; Perez JJ; Lopez-Corral L; Ocio EM; Garcia-Sanz R; Gutierrez NC; Jimenez-Ubieto A; Lahuerta JJ; Mateos MV; San Miguel JF
    Haematologica; 2015 Feb; 100(2):e53-5. PubMed ID: 25381128
    [No Abstract]   [Full Text] [Related]  

  • 77. Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics.
    Shaughnessy JD; Haessler J; van Rhee F; Anaissie E; Pineda-Roman M; Cottler-Fox M; Hollmig K; Zangari M; Mohiuddin A; Alsayed Y; Grazziutti M; Epstein J; Crowley J; Barlogie B
    Br J Haematol; 2007 Jun; 137(6):530-6. PubMed ID: 17489983
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Prognostic factors and risk stratification in chronic lymphocytic leukemia.
    Parikh SA; Shanafelt TD
    Semin Oncol; 2016 Apr; 43(2):233-40. PubMed ID: 27040701
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Identification of Prognostically Relevant Chromosomal Abnormalities in Routine Diagnostics of Multiple Myeloma Using Genomic Profiling.
    Kjeldsen E
    Cancer Genomics Proteomics; 2016; 13(2):91-127. PubMed ID: 26912802
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.
    Walker BA; Mavrommatis K; Wardell CP; Ashby TC; Bauer M; Davies F; Rosenthal A; Wang H; Qu P; Hoering A; Samur M; Towfic F; Ortiz M; Flynt E; Yu Z; Yang Z; Rozelle D; Obenauer J; Trotter M; Auclair D; Keats J; Bolli N; Fulciniti M; Szalat R; Moreau P; Durie B; Stewart AK; Goldschmidt H; Raab MS; Einsele H; Sonneveld P; San Miguel J; Lonial S; Jackson GH; Anderson KC; Avet-Loiseau H; Munshi N; Thakurta A; Morgan G
    Leukemia; 2019 Jan; 33(1):159-170. PubMed ID: 29967379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.